Ziolkowski Natalia, Milkovich John, D'Souza Alexandra, Austin Ryan E, McGuire Patricia, Lista Frank, Ahmad Jamil
Aesthet Surg J. 2025 Jan 16;45(2):148-155. doi: 10.1093/asj/sjae178.
Innovation in healthcare has led to the development of numerous implantable medical devices (IMDs). However, advances in our knowledge of breast implant-associated malignancies have raised questions about the prevalence, etiology, and management of malignancies associated with non-breast IMDs. The objective of this study was to examine the prevalence and characteristics of malignancies associated with non-breast IMDs. An expert medical librarian developed the search strategy for this review. Databases included MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. In addition, gray literature sources were searched, and relevant references from systematic reviews and meta-analyses were included. The PRISMA guideline was followed for the review. Risk of bias was evaluated with the JBI Critical Appraisal tools. A total of 12,230 articles were reviewed, with a total of 77 meeting inclusion criteria. Risk of bias was highest with case reports (moderate, average of 65.1% with range of 37.5% to 100%) and low for the remaining study types. In total, 616 cases of IMD-associated malignancies were identified. Malignancies associated with IMDs were reported in the head and neck (543, 88.1%), lower extremity (57, 9.6%), thorax (9, 1.4%), abdomen (3, 0.5%), and genitourinary system (2, 0.3%). The most common malignancy type in the lower extremity was sarcoma, in the head and neck was squamous cell carcinoma, and in the thorax was lymphoma. This study is the first comprehensive systematic review of its kind. Overall, the oncologic risk of IMDs is low. The discussion of malignancy is an important part of the overall consent process, and malignancy should be considered with any new signs or symptoms in the anatomic area of an implant. More data are needed to better understand how primary malignancies occur around IMDs and how to reduce this risk.
医疗保健领域的创新推动了众多可植入式医疗设备(IMD)的发展。然而,我们对乳房植入物相关恶性肿瘤的认识进展引发了关于非乳房IMD相关恶性肿瘤的患病率、病因及管理方面的问题。本研究的目的是调查非乳房IMD相关恶性肿瘤的患病率及特征。一位医学专业图书馆员为该综述制定了检索策略。数据库包括MEDLINE、Embase和Cochrane对照试验中央注册库。此外,还检索了灰色文献来源,并纳入了系统评价和荟萃分析中的相关参考文献。本综述遵循PRISMA指南。使用JBI批判性评价工具评估偏倚风险。共检索了12230篇文章,其中77篇符合纳入标准。病例报告的偏倚风险最高(中等,平均为65.1%,范围为37.5%至100%),其余研究类型的偏倚风险较低。总共确定了616例IMD相关恶性肿瘤病例。与IMD相关的恶性肿瘤报告部位包括头颈部(543例,88.1%)、下肢(57例,9.6%)、胸部(9例,1.4%)、腹部(3例,0.5%)和泌尿生殖系统(2例,0.3%)。下肢最常见的恶性肿瘤类型是肉瘤,头颈部是鳞状细胞癌,胸部是淋巴瘤。本研究是同类研究中的首次全面系统评价。总体而言,IMD的肿瘤学风险较低。恶性肿瘤的讨论是整个知情同意过程的重要组成部分,对于植入物解剖区域出现的任何新体征或症状都应考虑到恶性肿瘤的可能性。需要更多数据来更好地了解原发性恶性肿瘤在IMD周围如何发生以及如何降低这种风险。